QualityStocks Stock Newsletters Archives - Page 51 of 1818

TuesdayMay 15, 2012 10:44 am

Vision Industries Corp. (VIIC) Signs Green Truck Deal with $108 Million Potential

Vision Industries’ recent announcement that it has finalized a purchase order agreement with Total Transportation Services, Inc. (TTSI) represents a major step for the Gardena, California, company. Vision is a developer of zero emission electric/hydrogen hybrid powered vehicles and turnkey hydrogen fueling systems. The agreement with TTSI, one of the largest delivery carriers in Los Angeles and the Port of Long Beach, calls for an initial purchase from Vision of 100 Tyrano Class 8 Trucks, the nation’s first street legal zero emission Class 8 hydrogen/electric hybrid GVWR (Gross Vehicle Weight Rating) truck. The agreement also allows TTSI to purchase an…

TuesdayMay 15, 2012 9:44 am

Maxygen, Inc. (MAXY) to Receive $30 Million from Bayer Healthcare for Hemophilia Treatment Product Candidate

Maxygen announced that it will receive a $30.0 million payment from Bayer HealthCare LLC in connection with Bayer's clinical development of a recombinant factor VIIa product candidate for the treatment of hemophilia. Maxygen sold the recombinant factor VIIa product candidate (previously designated by Maxygen as MAXY-VII) to Bayer in July 2008 for an upfront cash payment of $90.0 million. The purchase included all of its other hematology assets. As of Monday, the additional $30.0 million contingent payment was based on the product candidate's further development by Bayer and was also subject to the satisfaction of certain patent related conditions -…

MondayMay 14, 2012 4:58 pm

VolitionRX Ltd. (VNRX) Completes $1M Financing to Begin Clinical Trials of Blood-based Diagnostics Tests

VolitionRX, a life sciences company focused on developing blood-based diagnostic tests, today announced it has raised $1.0 million through the closure of a private placement of 582,510 shares at $1.75 per share. The company will use the proceeds in part to fund clinical trials of VolitionRX's first NuQ™ test kits. The funds are allocated to initial clinical trials of VolitionRX's NuQ kits, blood-based diagnostic tests based on VolitionRX's Nucleosomics technology; as well as for ongoing capital needs. "We're delighted that we have raised over $1 million, which will allow us to begin clinical trials of our tests, both in-house and…

MondayMay 14, 2012 3:45 pm

Data Storage Corp. (DTST) Completes Phase I, II of Waltham Data Center Facility

Data Storage, a provider of cloud storage and cloud computing focused on data protection and business continuity solutions, today announced it has completed the first two phases of its three-phased expansion plan for its Waltham data center facility. The company says the phase 1 and 2 completions more than triple the company’s existing footprint with the additional installation of IBM's iSeries High Availability and Disaster Recovery server hardware and the new IBM iSeries Hosted Cloud solution. In addition to the added High Availability and Disaster Recovery capacity upgrades, the expansion also greatly increases the company's cloud-based offsite storage and data…

MondayMay 14, 2012 10:29 am

Gold Drops to 4 ½ Month Low on Euro Worries, Risk Off Trade

The risk off trade (sell everything) continued to extend to gold today as worries over the European debt crisis mounted. Continued political gridlock in Greece and problems in the Spanish banking system fed the doubts about the continent's economic viability and that of its currency, the euro, in its current state. Gold moved higher earlier this year, along with other riskier assets like stocks, as investors thought the euro crisis was receding. Spot gold hit a 4 ½ month low on Monday, dipping down to $1559.81 an ounce, its lowest point since December 2011. Gold closed in New York on…

MondayMay 14, 2012 10:28 am

American Standard Energy Corp. (ASEN) Reports Financial Results for First Quarter of 2012

American Standard Energy reported a sharp year-over-year increase in oil and gas revenues in the first quarter of 2012. The company also confirmed progress on the exploration and development of onshore oil and gas assets. American Standard Energy reported oil and gas sales of $5 million in the quarter ending March 31, 2012, up 109% from the $2.4 million recorded in the corresponding quarter of 2011. The company said that the increase was due to many factors, including higher production and higher realized prices for crude oil. American Standard Energy reported production of 68,137 barrels of oil equivalent (BOE) in…

MondayMay 14, 2012 8:57 am

Cover-All Technologies, Inc. (COVR) NexGen Business Intelligence Solution Featured in Recent Novarica Report

Cover-All Technologies, a Delaware corporation and leading developer of sophisticated software solutions for the property and casualty insurance industry, announced its business intelligence (BI) solution, NexGen Business Intelligence, has been included in a Novarica report profiling insurance BI solutions. Novarica is a research and advisory firm focused on insurance technology strategy. The report, “Business Intelligence Solutions for U.S. Insurers 2012 (Q1),” profiles 19 vendors that currently offer BI solutions. The report describes the growing importance of BI and key areas of use by property/casualty insurance companies. According to Martina Conlon, principal for Novarica’s insurance team and author of the report,…

FridayMay 11, 2012 3:54 pm

Cardium Therapeutics, Inc. (CXM) Growing Footprint in Health Sciences and Regenerative Medicine Space

Cardium Therapeutics has built a name for itself by capturing innovative biomedical technologies that emerge in the health sciences and regenerative medicine space, while simultaneously developing its own technology portfolio. By focusing on underserved demand and products/business opportunities with a clear path to monetization, CXM has been able to create a lightweight approach that harnesses all of the external partner, market, and technology strengths, while avoiding the cost structure pitfalls that plague many other operators in the same sector. The envelope of medical business opportunities CXM has assembled to date includes the in-house MedPodium® Health Sciences healthy lifestyle product platform,…

FridayMay 11, 2012 3:29 pm

CytoSorbents Corp. (CTSO) CEO Named as Finalist for Ernst & Young Entrepreneur of the Year 2012

CytoSorbents, a critical care-focused company using blood purification to modulate the immune system and fight multi-organ failure in life-threatening illnesses, today announced its CEO, Dr. Phillip Chan, was named as a finalist in the Ernst & Young Entrepreneur Of The Year® 2012 program, which recognizes entrepreneurs with demonstrated success in areas such as innovation, financial performance, and personal commitment. Dr. Chan was selected by an independent judging panel comprised of previous winners, CEOs, private capital investors, and other regional business leaders. Since his appointment as CytoSorbents CEO and president in 2009, Dr. Chan has taken initiatives to build the company…

FridayMay 11, 2012 3:24 pm

European Medicines Agency Awards Arno Therapeutics, Inc. (ARNI) AR-42 Orphan Drug Designation

Arno Therapeutics, a clinical-stage company focused on developing products for the treatment of cancer, today announced that its investigational compound AR-42 has been granted orphan-drug designation by the European Medicines Agency’s (EMA) Committee for Orphan Medicinal Products for the treatment of neurofibromatosis type 2 (NF2), a rare genetic disorder characterized by the growth of noncancerous tumors in the brain and spinal cord, juvenile cataracts, and neurofibromas of the skin. The EMA grants orphan-drug designation for medicines designed to treat life-threatening or debilitating conditions affecting no more than five in 10,000 people, and allows the developer to obtain inspection-fee reductions, protocol…

Site Search

Company Search

Category: QualityStocks Stock Newsletters